<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Asthma Allergy and Lung Biology</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1244339E-4070-4346-842C-EAB736E8A261"><gtr:id>1244339E-4070-4346-842C-EAB736E8A261</gtr:id><gtr:firstName>Tak</gtr:firstName><gtr:surname>Lee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/95C0601F-3A0B-496E-B290-6F131EB6A764"><gtr:id>95C0601F-3A0B-496E-B290-6F131EB6A764</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Corrigan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/85F4F906-8476-4AEC-9B1B-818D2496249B"><gtr:id>85F4F906-8476-4AEC-9B1B-818D2496249B</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>Durham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C68DCAD6-AB77-43CC-AEAF-45EB93348FA8"><gtr:id>C68DCAD6-AB77-43CC-AEAF-45EB93348FA8</gtr:id><gtr:firstName>Hannah</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Gould</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0200485"><gtr:id>B351FFC2-5BA3-45C1-8A8D-5D3D2F11F62C</gtr:id><gtr:title>Local heavy-chain switching to IgE in non-atopic asthma: a new concept in disease pathogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200485</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-08-11</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-12-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>221825</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Novartis Collaboration</gtr:description><gtr:id>933D15A2-20D1-48B5-880A-A3B5082CBEFD</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:partnerContribution>Intellectual exchange
Funding for research fellow
Provision of omalizumab and placebo to GCP standard</gtr:partnerContribution><gtr:piContribution>Investigated effects of omalizumab in non-atopic asthma, using a proof of concept clinical study backed by immunohistochemistry from bronchial biopsies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BLF Webinar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C9F122BC-BFE5-4168-8019-19C5BC54BF98</gtr:id><gtr:impact>65 asthma patiernts participated in Webinar organised by the Bristish Lung Foundation for a discsssion on the role of allergy and allergen avoidance in asthma

Much appreciative feedback to the British Lung Foundation</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Birmingham Science Fair</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BFEEEC6B-A1B0-4A96-A754-EF92CDC05CB1</gtr:id><gtr:impact>60 members of the lay public, some asthma sufferers and press, Questions and discussion. Press releases and local press articles.

Asthma UK reported surge in web site interest.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centre web site</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7F541A09-A664-433A-8091-5D4F531530FB</gtr:id><gtr:impact>Web site and press relaeses

Asthma UK made aware of the possibility that omalizumab may in theory be suirable to treat non-atopic patients</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>420000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Boehringer Ingelheim</gtr:department><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>C.H. Boehringer Sohn AG &amp; Ko. KG</gtr:fundingOrg><gtr:id>8C8A3A21-49C2-40CA-9CEF-EA9BD732C167</gtr:id><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>360000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The role of IgE antibodies in non-atopic asthma</gtr:description><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>EDA01E1B-7EF7-4651-B4DF-0B1EA5C994F8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>370000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's and St. Thomas' Charity Clinical Translational Award Scheme</gtr:description><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:id>2698A0E7-E3A1-4FAC-9241-D880929B73FA</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>280000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Unrestricted research grant from Novartis Pharmaceuticals</gtr:description><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>D007634C-D6DD-4DFA-BC7F-9C33B15651E8</gtr:id><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4761430</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>United Kingdom Refractory Asthma Stratification Programme (RASP-UK)</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/M016579/1</gtr:fundingRef><gtr:id>CF16B47C-4359-4FCA-AA21-504A565E79CD</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE national consultation on omalizumab therapy</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F3E599ED-64FF-4FC5-836B-6A1C1D78C93B</gtr:id><gtr:impact>None as yet but may lead to reassessment of omalizumab therapy for the treatment of non-atopic asthma, and has encouraged Novartis, the manufacturers, to evaluate new anti-IgE therapies in non-atopic asthmatics</gtr:impact><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Expert witness to House of Lords Science and Technology Committee 6th Report HL 166</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EAA52FE9-4402-451F-ADB2-1237989A7AB7</gtr:id><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>RASP-UK</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>17E00BD1-27EE-4681-918D-5C3B8AA9B654</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>By observing the synthesis of IgE in the bronchial mucosa of non-atopic asthmatics we identified IgE as a therapeutic target in these patients even though they do not have positive skin prick tests.</gtr:description><gtr:id>B885898F-83DB-46B4-A6A4-ECD5A23C6F46</gtr:id><gtr:impact>This has resulted in the part funding by Novartis, manufacturers of omalizumab, of a phase II proof of concept trial of the therapeutic effect of omalizumab in non-atopic asthma. If ratified this treatment could then be made available for thousands of severe, non-atopic asthmatics throughout the UK.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Use of anti-IgE therapy in non-atopic asthma</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>In house allergen compoent resolved diagnosis (ISAC) facility</gtr:description><gtr:id>C74FC6D7-E64D-4D3E-8D3F-58FB05D404CC</gtr:id><gtr:impact>Analysis of the IgE repertoire in biological samples such as bronchial biopsies</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ISAC</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Elisa for detevtion of human IgG aotoantibodies against IgE or the high-affinity IgE-receptor FceRI.</gtr:description><gtr:id>AE0369DC-5A3F-44B2-94D7-95CC37993629</gtr:id><gtr:impact>Rapid screeeing tool for subset of non-atopic asthmartics expressing such antibodies.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IgE autoantibody ELISA</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>sSyetm for direct, ex vivo culture of resected nasal polyps from patients with aspirin sensitive rhinosinusitis to study eicoasoind metablism and its regulation by drugs such as COX-1 inhibitors usinmg cell proportions directly exe vivo</gtr:description><gtr:id>7299D29E-C137-457C-83AB-B80E8ECC89BA</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Ex vivo prostanoid production</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90AAFC5E-7FD3-4E96-8986-46D61B867039"><gtr:id>90AAFC5E-7FD3-4E96-8986-46D61B867039</gtr:id><gtr:title>Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT).</gtr:title><gtr:parentPublicationTitle>NPJ primary care respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/74d2fa34d6696cedddc979bcc8e5a992"><gtr:id>74d2fa34d6696cedddc979bcc8e5a992</gtr:id><gtr:otherNames>Levy ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2055-1010</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FE2C0B2-B165-4D33-AFE4-ACD34258BECB"><gtr:id>7FE2C0B2-B165-4D33-AFE4-ACD34258BECB</gtr:id><gtr:title>Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0b1480f9c31d6e8295beb745262209f5"><gtr:id>0b1480f9c31d6e8295beb745262209f5</gtr:id><gtr:otherNames>Takhar P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C967FC70-5CE2-4B3A-AD5E-42E8D4FE422B"><gtr:id>C967FC70-5CE2-4B3A-AD5E-42E8D4FE422B</gtr:id><gtr:title>Cigarette smoking increases bronchial mucosal IL-17A expression in asthmatics, which acts in concert with environmental aeroallergens to engender neutrophilic inflammation.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1bbabdd663590872f390c5e0e71c5ed"><gtr:id>b1bbabdd663590872f390c5e0e71c5ed</gtr:id><gtr:otherNames>Siew LQ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/60DF3EBA-6576-4457-93A5-C1A0D6C06FDD"><gtr:id>60DF3EBA-6576-4457-93A5-C1A0D6C06FDD</gtr:id><gtr:title>Allergen-specific IgE is not detectable in the bronchial mucosa of nonatopic asthmatic patients.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef7c28364091703ea4a24642a8561606"><gtr:id>ef7c28364091703ea4a24642a8561606</gtr:id><gtr:otherNames>Pillai P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E27CC6B8-05FE-4ED7-8425-9C5B8ADCCCB0"><gtr:id>E27CC6B8-05FE-4ED7-8425-9C5B8ADCCCB0</gtr:id><gtr:title>Epidemiological associations of allergy, IgE and cancer.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f5cf125bb61b8a825e1364b81e3ebd6"><gtr:id>3f5cf125bb61b8a825e1364b81e3ebd6</gtr:id><gtr:otherNames>Josephs DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E01C125-E92D-49F6-A4D6-312EFB3AC591"><gtr:id>7E01C125-E92D-49F6-A4D6-312EFB3AC591</gtr:id><gtr:title>Counter regulation of the high affinity IgE receptor, FcepsilonRI, on human airway dendritic cells by IL-4 and IL-10.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b76e9d83fe8a9ae8690c5ae5c4595cc8"><gtr:id>b76e9d83fe8a9ae8690c5ae5c4595cc8</gtr:id><gtr:otherNames>Faith A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C08C77B2-D231-4E9B-964F-B2D9F1A89BA9"><gtr:id>C08C77B2-D231-4E9B-964F-B2D9F1A89BA9</gtr:id><gtr:title>&amp;quot;Auto-anti-IgE&amp;quot;: naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cfc1c2bbda309923a8199de5d2aedfb5"><gtr:id>cfc1c2bbda309923a8199de5d2aedfb5</gtr:id><gtr:otherNames>Chan YC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AEF2635B-CD99-4C83-BB2F-7446998AD288"><gtr:id>AEF2635B-CD99-4C83-BB2F-7446998AD288</gtr:id><gtr:title>Germinal-centre reactions in allergic inflammation.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d366311edfeaa1ca0c49c81e1c1a6e0a"><gtr:id>d366311edfeaa1ca0c49c81e1c1a6e0a</gtr:id><gtr:otherNames>Gould HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D644AB4-B8D9-41D9-B811-000D6A8306E6"><gtr:id>0D644AB4-B8D9-41D9-B811-000D6A8306E6</gtr:id><gtr:title>Prevalence, determinants and clinical correlates of vitamin D deficiency in adults with inhaled corticosteroid-treated asthma in London, UK.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e153d31b0ad14e6f7f06a2a5603f548f"><gtr:id>e153d31b0ad14e6f7f06a2a5603f548f</gtr:id><gtr:otherNames>Jolliffe DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/549E2567-C564-4387-B6D0-3316068B2909"><gtr:id>549E2567-C564-4387-B6D0-3316068B2909</gtr:id><gtr:title>Nasal administration of interleukin-33 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma surrogate.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4f0282aaf2cf3a127cbafb302fc2f208"><gtr:id>4f0282aaf2cf3a127cbafb302fc2f208</gtr:id><gtr:otherNames>Shan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7DC72555-1E0C-45B1-A3A7-1058F78BE525"><gtr:id>7DC72555-1E0C-45B1-A3A7-1058F78BE525</gtr:id><gtr:title>Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef7c28364091703ea4a24642a8561606"><gtr:id>ef7c28364091703ea4a24642a8561606</gtr:id><gtr:otherNames>Pillai P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7108D078-82CA-4172-9498-29427FCF1979"><gtr:id>7108D078-82CA-4172-9498-29427FCF1979</gtr:id><gtr:title>Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling by the PI3K inhibitor LY294002.</gtr:title><gtr:parentPublicationTitle>Respirology (Carlton, Vic.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a75ed317b835fa04bc2ece4fa173be04"><gtr:id>a75ed317b835fa04bc2ece4fa173be04</gtr:id><gtr:otherNames>Huang P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1323-7799</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2488BABF-CDA0-4B2E-B2CC-F2599D550C6E"><gtr:id>2488BABF-CDA0-4B2E-B2CC-F2599D550C6E</gtr:id><gtr:title>Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial.</gtr:title><gtr:parentPublicationTitle>JAMA internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5638cdb8eec944bcf9fe079c92dd7fe8"><gtr:id>5638cdb8eec944bcf9fe079c92dd7fe8</gtr:id><gtr:otherNames>Johnston SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6106</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200485</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>